Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing

25 Jun 2018

• By Sten Stovall

CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.

Coins — CEO Says NodThera Now Has Funding To Move Into The Clinic • Source: Shutterstock

Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing

More from Strategy

More from Business